Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 40Other solid neoplasm 7Gastrointestinal 5Gynecologic 4Genitourinary 4CNS 4Thoracic 3Tumor-Agnostic 2Head & Neck 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 3Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dysgerminoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Lapatinib × Gynecologic × Clear all
NCT04608409 2025-06-29

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

University of Kentucky

Phase 1 Completed
16 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

NCT00313599 2014-07-02

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

University of California, San Francisco

Phase 1 Completed
28 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT01454479 2011-10-19

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Chang Gung Memorial Hospital

Phase 1 Unknown
24 enrolled
Gynecologic

Endometrial Neoplasms

NCT00317434 2009-12-15

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

University of Alabama at Birmingham

Phase 1 Terminated
12 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡